Dow Turns Higher; Nasdaq Jumps Over 200 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 60 points on Friday.
Nasdaq Surges 100 Points; Crude Oil Rises Sharply
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining 100 points on Friday.
5 Analysts Have This to Say About Sight Sciences
Within the last quarter, Sight Sciences (NASDAQ:SGHT) has observed the following analyst ratings:
Morgan Stanley Maintains Overweight Rating for Sight Sciences: Here’s What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Sight Sciences (NASDAQ:SGHT) and lower its price target from $14.00 to $10.00.
Shares of Sight Sciences are trading down 3.39% over the last 24 hours, at $5.70 per share.
Morgan Stanley Maintains Overweight on Sight Sciences, Lowers Price Target to $10
Morgan Stanley analyst Cecilia Furlong maintains Sight Sciences (NASDAQ:SGHT) with a Overweight and lowers the price target from $14 to $10.
Sight Sciences’ Near-Term Upside Is Limited, Says This Analyst
Needham initiated coverage on Sight Sciences Inc (NASDAQ:SGHT) with a Hold rating and no price target. The analyst warns that the recent competitive…
Needham Initiates Coverage On Sight Sciences with Hold Rating
Needham analyst David Saxon initiates coverage on Sight Sciences (NASDAQ:SGHT) with a Hold rating.
Sight Sciences To Feature Interactive Panel Discussions Of Real-World Use Of The OMNI Surgical System As A Standalone Glaucoma Treatment At American Academy Of Ophthalmology Annual Meeting October 1-2
MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a